CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 42,534 enrolled
Drug / intervention
Dabigatran vs. Rivaroxaban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03026556
NCT03026556N/ACompleted
CompareCT.gov

Safety and Effectiveness Study Comparing Dabigatran, Rivaroxaban & Apixaban in Non-valvular Atrial Fibrillation Patients Enrolled in the US Department of Defense Military Health System

Boehringer Ingelheim·observational·Posted Jan 20, 2017·Updated Jun 3, 2019

In Brief

An observational study evaluating Dabigatran vs. Rivaroxaban and Dabigatran vs. Apixaban for Atrial Fibrillation. Completed, enrolled 42,534 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the safety and effectiveness of newly initiated dabigatran among patients diagnosed with non valvular atrial fibrillation (NVAF) in comparison to newly initiated rivaroxaban users and newly initiated apixaban users

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesUnited States
CollaboratorsHealth ResearchTx, LLC (HRTX), inVentiv Health Clinical (iVH), United States Department of Defense (DOD)

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJan 20, 2017
Enrollment StartDec 29, 2016
Primary CompletionAug 23, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.5 years ago

Interventions

Dabigatran vs. Rivaroxabandrug

observed for 6 years

Dabigatran vs. Apixabandrug

Observed for 6 years